Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Shoots For Top Three In Pain And Respiratory

Executive Summary

Teva’s new management has homed in on pain and respiratory disease as two core therapeutic areas. During the firm’s second quarter earnings call, CEO Erez Vigodman gave a sneak peek at his comprehensive portfolio review.

Advertisement

Related Content

Teva Zecuity's Safety: Burns Go From Non-Issue In Label To Product Puller
Teva’s Focus On Its Core Means Increased Outlicensing Action
Teva Ends Oncology, Women’s Health R&D Following Strategic Review
Teva Ends Oncology, Women’s Health R&D Following Strategic Review
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Teva Changes Its Tune On Substitutable Generic Advair
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel